blinatumomab   Click here for help

GtoPdb Ligand ID: 7384

Synonyms: Blincyto® | bscCD19xCD3 | MEDI-538 | MT-103 | MT103 [2]
Approved drug Immunopharmacology Ligand
blinatumomab is an approved drug (FDA (2014), EMA (2015))
Compound class: Antibody
Comment: Blinatumomab is a monoclonal antibody with anti-cancer effects. Its mechanism of action classifies this antibody as a member of the bi-specific T-cell engager (BiTE®) group of engineered antibodies. It was the first biologic of this class to gain clinical approval.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help
References
1. Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ. (2017)
Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Leukemia, 31 (4): 777-787. [PMID:28028314]
2. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P et al.. (2007)
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
J. Immunother., 30 (8): 798-807. [PMID:18049331]
3. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA. (2002)
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.
Int. J. Cancer, 100 (6): 690-7. [PMID:12209608]
4. Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA et al.. (2018)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Blood, 131 (14): 1522-1531. [PMID:29358182]
5. Kufer P, Lutterbuse R, Kohleisen B, Zeman S, Bauerle P. (2009)
Single chain antibody construct comprising binding domains specific for human CD3 and human CD19.
Patent number: US7635472. Assignee: Micromet Ag. Priority date: 31/05/2003. Publication date: 22/12/2009.
6. Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA. (2007)
CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mol. Immunol., 44 (8): 1935-43. [PMID:17083975]
7. Slaney CY, Wang P, Darcy PK, Kershaw MH. (2018)
CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment.
Cancer Discov, 8 (8): 924-934. [PMID:30012854]